Raia Drogasil S.A.
Raia Drogasil S.A. (RADLY) Revenue
Annual & quarterly revenue history · segment & region breakdown
RADLY · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsRaia Drogasil S.A. trailing twelve-month (TTM) revenue is $44.95B, an increase of 11.62% year-over-year from $43.38B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $43.38B | +$4.52B | +11.62% |
| 2024-12-31 | $38.86B | +$4.89B | +14.40% |
| 2023-12-31 | $33.97B | +$4.91B | +16.88% |
| 2022-12-31 | $29.07B | +$4.94B | +20.48% |
| 2021-12-31 | $24.13B | +$4.06B | +20.23% |
| 2020-12-31 | $20.07B | +$2.50B | +14.24% |
| 2019-12-31 | $17.57B | +$2.76B | +18.67% |
| 2018-12-31 | $14.80B | +$1.59B | +12.03% |
| 2017-12-31 | $13.21B | +$1.96B | +17.38% |
| 2016-12-31 | $11.26B | +$2.36B | +26.51% |
Compare revenue vs peers
Medical - PharmaceuticalsCompare RADLY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Raia Drogasil S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Raia Drogasil S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in BRL.
Data sourced from Raia Drogasil S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RADLY revenue · 4 questionsRADLY's trailing twelve-month (TTM) revenue is $44.95B. That is an increase of 11.62% year-over-year from $43.38B in FY2025.
▸ Source: FMP · Raia Drogasil S.A. SEC filings · GAAP · Raia Drogasil S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026